ArticleCureus2025
Beneficial Effect of Polydeoxyribonucleotide in the Treatment of Actinic Cheilitis: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Actinic cheilitis (AC) is considered a potentially malignant disorder characterized by epithelial atrophy, chronic inflammation, and the progressive deterioration of the tissue architecture of the vermilion border of the lip. Currently, there is no effective minimally invasive treatment to reverse the progression of this pathology. The use of polydeoxyribonucleotide (PDRN) has demonstrated benefits across various dermatologic and wound-healing contexts due to its regenerative, angiogenic, and anti-inflammatory properties. This study aims to evaluate the healing effect of PDRN on AC lesions. This report describes the case of a 59-year-old woman with an ulcerated lesion persisting for more than two to three weeks on her lower lip, diagnosed as AC. Previous treatments with creams were unsuccessful and led to recurrence. A single subdermal infiltration of PDRN resulted in the restoration of epithelial integrity, reduced tissue fragility, and a significant improvement in oral function; that is, the patient can laugh and eat without pain after 21 days of treatment. These findings suggest that PDRN therapy is a minimally invasive option for tissue repair in AC, with potential preventive value against progression to squamous cell carcinoma. Further clinical studies are needed to confirm these results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.